In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 1, 1999, Pages 559-564

  Bergamo, A ^a   Gagliardi, R ^a   Scarcia, V ^a   Furlani, A ^a   Alessio, E ^a   Mestroni, G ^a   Sava, G ^a,b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b Callerio Foundation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; IMIDAZOLIUM IMIDAZOLEDIMETHYLSULFOXIDE TETRACHLORORUTHENATE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELL CYCLE PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FLOW CYTOMETRY; INTRAPERITONEAL DRUG ADMINISTRATION; LEWIS CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH;

EID: 0032921951     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Alvarez Boo P, Casas JS, Couce MD, Freijanes E, Furlani A, Scarcia V, Sordo J, Russo U and Varela M (1997) Synthesis, characterisation and cytotoxic activity of complexes of diorganotin(IV) halides with N-methyl-2,2′-bisimidazole. Appl Organometallic. Chem 11:963-968.
2. Capozzi I, Clerici K, Cocchietto M, Salerno G, Bergamo A and Sava G (1998) Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry. Chem-Biol Interact 113:51-64.
3. Clarke MJ, Galang RD, Rodriguez VM, Kumar R, Pell S and Bryan DM (1988) Chemical considerations in the design of ruthenium anticancer agents, in Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (Nicolini Med) pp 582-601, Martinus Nijhoft Pub., Boston.
4. Clarke MJ and Stubbs M (1996) Interactions of metallopharmaceuticals with DNA, in Metal Ions in Biological Systems (Sigel A and Sigel H eds) pp 727-780, Marcel Dekker, New York.
5. Cleare MJ and Hydes PC (1979) Anti-tumour properties of metal complexes, in Metal Ions in Biological Systems (Helmut Siegel ed) pp 1-62, Marcel Dekker, New York.
6. 4(Dmso)Im] after acute treatment in mice. Pharmacol Res, in press.
7. Craciunescu DG, Scarcia V, Furlani A, Doadrio A, Ghirvu C and Ravalico L (1987) Cytostatic and antitumour properties of a new series of Pt(II) complexes with cyclopentylamine. In Vivo 1:229-234.
8. Deinum J, Wallin M and Jensen PW (1985) The binding of Ruthenium Red to tubulin. Biochim Biophys Acta 838:197-205.
9. Eagle H (1959) Amino acid metabolism in mammalian cell cultures. Science 130: 432-437.
10. Fidler IJ and Balch CM (1987) The biology of cancer metastasis and implications for therapy. Curr Probl Surg 24:129-209.
11. Fox SB, Turne GD, Leek RD. Whitehouse RM, Gatter KC and Harris AL (1995) The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumour endothelium. Breast Cancer Res Treat 36:219-226.
12. 4(DMSO)Im) in the mouse. Clin Exp Metastasis 12:93-100.
13. Ghosh L, Nassauer J, Faiferman I and Ghosh BC (1981) Ultrastructural study of membrane glycocalix in primary and metastatic human and rat mammary carcinoma. J Surg Ontol 17:395-401.
14. Giraldi T, Sava G, Bertoli G, Mestroni G and Zassinovich G (1977) Antitumor action of two rhodium and ruthenium complexes in comparison with cis-diamminedi-chloro platinum(II). Cancer Res 37:2662-2666.
15. Mestroni G, Alessio E and Sava G (1998) New salts of anionic complexes of Ru(III) as antimetastatic and antineoplastic agents. International Patent PCT C 07F 15/00, A61K 31/28, WO 98/00431.
16. Poste G (1986) Pathogenesis of metastatic disease: Implications for current therapy and for the development of new therapeutic strategies. Cancer Treat Rep 70:183-199.
17. Rozencweig M, von Hoff DD, Slavik M and Muggia F (1977) Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Int Med 86:803-812.
18. Sava G (1994) Ruthenium compounds in cancer therapy, in Metal Compounds in Cancer Therapy (Fricker SP ed) pp 65-91, Chapman & Hall, London.
19. Sava G and Bergamo A (1997) Pharmacological control of solid tumour metastases by ruthenium complexes. Curr Top Pharmacol 3:207-216.
20. Sava G, Capozzi I, Bergamo A, Gagliardi R, Cocchietto M, Masiero L, Onisto M, Alessio E, Mestroni G and Garbisa S (1996) Down regulation of tumor gelatinase/ inhibitor balance and preservation of tumor endothelium by an antimetastatic ruthenium complex. Int J Cancer 68:60-66.
21. Sava G, Pacor S, Bergamo A, Cocchietto M, Mestroni G and Alessio E (1995) Effects of ruthenium complexes on experimental tumours: Irrelevance of cytotoxicity for metastasis inhibition. Chem-Biol Interact 95:109-126.
22. 4(DMSO)Im]. Selective inhibition of spontaneous lung metastases by the ruthenium complex. Drug Invest 8:150-161.
23. Sava G, Zorzet S, Giraldi T, Mestroni G and Zassinovich G (1984) Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cisPDD in mice bearing solid malignant neoplasms. Eur J Cancer Clin Oncol 20:841-847.
24. Schadendorf D, Heidel J, Gawlik C, Suter L and Czametzki BM (1995) Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanomas as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 87:366-371.
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
26. Tognella S (1990) Pharmacological interventions to reduce platinum-induced toxicity. Cancer Treat Rev 17:139-142.
27. Umansky V, Schirrmacher V and Rocha M (1996) New insights into tumor-host interactions in lymphoma metastasis. J Mol Med 74:353-363.